383 results on '"Lacombe, Denis"'
Search Results
102. Abstract C220: Combining novel targeted therapies and radiotherapy: A challenge to overcome.
103. How can innovative forms of clinical research contribute to deliver affordable cancer care in an evolving health care environment?
104. International clinical trials setting for rare cancers: organisational and regulatory constraints—the EORTC perspective
105. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033).
106. Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
107. Academia–Industry Partnerships: Are we ready for new models of partnership?
108. EORTC 24051: Unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma
109. Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD).
110. EORTC Radiation Oncology Group quality assurance platform: Establishment of a digital central review facility
111. Prediction of early death among patients (pts) enrolled in phase I trials: Development and validation of a new model based on platelet count and albumin level.
112. Personalised medicine in oncology: questions for the next 20 years
113. Glufosfamide: can we improve the process of anticancer agent development?
114. Imaging biomarker roadmap for cancer studies
115. Integrating Collection of Biospecimens in Clinical Trials: The Approach of the European Organization for Research and Treatment of Cancer
116. International investigator-driven clinical trials: challenges and opportunities for US–Europe cooperation through the US cooperative group networks
117. The EORTC Cutaneous T-Cell Lymphoma (CTCL) Platform
118. Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
119. Design and performance of clinical trials in head and neck cancer
120. IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
121. Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041)
122. EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma
123. MGMT Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951
124. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951
125. Improving Cancer Outcomes Through International Collaboration in Academic Cancer Treatment Trials
126. Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
127. Individual patient data analysis to assess modifications to the RECIST criteria
128. Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
129. Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: A study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001)
130. Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: Results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882)
131. Health-Related Quality of Life in Patients Treated for Anaplastic Oligodendroglioma With Adjuvant Chemotherapy: Results of a European Organisation for Research and Treatment of Cancer Randomized Clinical Trial
132. Prognostic Value of Health-Related Quality-of-Life Data in Predicting Survival in Patients With Anaplastic Oligodendrogliomas, From a Phase III EORTC Brain Cancer Group Study
133. The Conduct of Clinical Trials for Medicinal Products in Europe in the Light of the European Clinical Trials Directive. Review of Regulatory and Practical Aspects in the Different Countries
134. Conduite des essais cliniques de médicaments au niveau européen depuis la directive européenne essais cliniques. Revue des aspects réglementaires et pratiques dans différents pays
135. Clinical trial design limitations in head and neck squamous cell carcinomas
136. Using the continual reassessment method: Lessons Learned from an EORTC phase I dose finding study
137. Phase I Combining a P-Glycoprotein Inhibitor, MS209, in Combination with Docetaxel in Patients with Advanced Malignancies
138. Imaging biomarker roadmap for cancer studies
139. European Organisation for Research and Treatment of Cancer's point of view
140. New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials.
141. EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.
142. A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054).
143. SAE Report Handling in a Multinational Academic Research Environment.
144. La comédie visuelle, démystification
145. Imaging biomarker roadmap for cancer studies
146. Steps forward for cancer precision medicine
147. ‘Mind the gap’ between the development of therapeutic innovations and the clinical practice in oncology: A proposal of the European Organisation for Research and Treatment of Cancer (EORTC) to optimise cancer clinical research.
148. Analysis of the characteristics and the degree of pragmatism exhibited by pragmatic-labelled trials of antineoplastic treatments.
149. Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer.
150. EBCC-14 manifesto: Addressing disparities in access to innovation for patients with metastatic breast cancer across Europe.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.